medicament "Pregabalin-Darnitsa" is used at the following indications:

• neuropatichesky pain: treatment of neuropatichesky pain of peripheral or central origin at adults;
• epilepsy: additional therapy in partial convulsive attacks with secondary generalization or without that at adults;
• generalized anxiety disorder: treatment of a generalized anxiety disorder at adults;
• fibromyalgia.

Structure

• active ingredient: pregabalin;
• 1 capsule contains pregabalin 300 mg;
• other components: lactose monohydrate, starch corn, talc; solid gelatin capsules: gelatin, titanium dioxide (E 171).

Contraindication

Hypersensitivity to active ingredient to or to any of medicine excipients.

Route of administration

Dose

Range of medicament doses can change within 150–600 mg/days. The daily dose is distributed on 2 or 3 receptions.

Neuropatichesky pain

with the dose 150 mg/days distributed on 2 or 3 receptions. Depending on the individual answer and tolerance of medicine the patient it is possible to increase a dose to 300 mg a day in 3-7 days, and if necessary to the maximum dose of 600 mg a day after 7 days.

Epilepsy

with the dose 150 mg/days distributed on 2 or 3 receptions. Depending on the individual answer and tolerance of medicine the patient it is possible to increase a dose to 300 mg/days after the first week of treatment. In one week the dose can be increased to maximum – 600 mg/days

Generalized anxiety disorder

Dose distributed on 2 or 3 receptions can change within 150–600 mg/days. Periodically it is necessary to reconsider need of continuation of therapy.

with a dose 150 mg/days. Depending on the individual answer and tolerance of medicine the patient it is possible to increase a dose to 300 mg/days after the first week of treatment. After one more week of reception it is possible to increase a dose to 450 mg/days. In one week the dose can be increased to maximum – 600 mg/days

Feature of use

According to the operating clinical practice some patients with diabetes which body weight increased during therapy pregabaliny, can demand dose adjustment of antihyperglycemic medicines.

Pregnant

Medicine should not be applied during pregnancy needlessly (when the advantage for mother obviously exceeds possible risk for a fruit).

Safety and efficiency of a pregabalin at its use are not established to children (up to 18 years) by

.

Drivers

Medicine can have insignificant or moderate impact on ability to run vehicles and to work with other mechanisms. Can cause dizziness and drowsiness that will affect ability to run vehicles and to work with other mechanisms. In this regard patients should recommend to abstain from control of vehicles, from work with a difficult technique and other potentially dangerous activity, it will not become known yet whether this medicine affects their ability to such activity.

Most frequent side reactions at overdose of a pregabalin the drowsiness, confusion of consciousness, excitement and concern were p>

. Also messages about spasms arrived.

Side effects

from a liver and biliary tract: the increased level of liver enzymes, jaundice, a liver failure, hepatitis.

from kidneys and an urinary system: urine incontinence, a dysuria, an albuminuria, a hamaturia, formation of stones in kidneys, nephrite, a renal failure, an oliguria, an ischuria, an acute renal failure, a glomerulonephritis, pyelonephritis.

from a metabolism, metabolism: increase in appetite, loss of appetite, hypoglycemia.

to Store

in original packing at a temperature not above 25 °C. To store out of children's reach.